Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat

• Published in: Leukemia research Vol. 38; no. 7; pp. 816 - 821
• Main Authors: Andersen, Christen Lykkegaard, Bjørn, Mads Emil, McMullin, Mary Frances, Harrison, Claire, Samuelsson, Jan, Ejerblad, Elisabeth, Zweegman, Sonja, Fernandes, Savio, Bareford, David, Knapper, Steven, Löfvenberg, Eva, Linder, Olle, Andreasson, Bjørn, Ahlstrand, Erik, Jensen, Morten Krogh, Bjerrum, Ole Weis, Vestergaard, Hanne, Larsen, Herdis, Klausen, Tobias Wirenfeldt, Mourits-Andersen, Torben, Skov, Vibe, Thomassen, Mads, Kruse, Torben, Grønbæk, Kirsten, Hasselbalch, Hans Carl
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.07.2014
• Subjects: Adipokines - blood; Adult; Aged; Aged, 80 and over; C-Reactive Protein - analysis; Chitinase-3-Like Protein 1; Essential thrombocythemia; Female; Hematology, Oncology and Palliative Medicine; Histone Deacetylase Inhibitors - therapeutic use; Humans; Hydroxamic Acids - adverse effects; Hydroxamic Acids - therapeutic use; Lectins - blood; Male; Medicin och hälsovetenskap; Middle Aged; Phase II study; Polycythemia vera; Polycythemia Vera - blood; Polycythemia Vera - drug therapy; Thrombocythemia, Essential - blood; Thrombocythemia, Essential - drug therapy; Vorinostat; Yk1-40; Ykl-40; Essential thrombocythemia; Phase II study; Polycythemia vera; Ykl-40; Vorinostat
• ISSN: 0145-2126; 1873-5835; 1873-5835
• DOI: 10.1016/j.leukres.2014.04.002

Abstract YKL-40 regulates vascular endothelial growth factors and induces tumor proliferation. We investigated YKL-40 before and after treatment with vorinostat in 31 polycythemia vera (PV) and 16 essential thrombocythemia (ET) patients. Baseline PV patient levels were 2 times higher than in healthy controls ( P < 0.0001) and 1.7 times higher than in ET ( P = 0.02). A significant correlation between YKL-40 at baseline and neutrophils, CRP, LDH, JAK2 V617F and platelets in PV patients was observed, as well as a significantly greater reduction of YKL-40 levels in PV patients responding to therapy. YKL-40 might be a novel marker of disease burden and progression in myeloproliferative neoplasms.